Breast cancer is top one in the pathogenesis of malignant tumor in female.

The NCCN guidelines for breast cancer points out in recent year that for patients with breast cancers, HER2 testing should be done before treatment. The first recommendation for patients with ectopic expression of HER2 is the administration of trastuzumab and pertuzumab. Target therapy for breast cancer has a better curative effect and less toxic side effects compared to traditional chemotherapy. It patients are carriers of germ line mutations of BRCA1/2, indicating they are positioned with high risk of recurrence, they may need to do bilateral surgical resection instead of unilateral surgery after breast conserving surgery. For high risk population with family hereditary breast / ovarian cancers, NCCN guidelines recommend a breast self-exam, enhanced imaging, corresponding serum tumor marker testing and medication prevention should be done routinely. It also recommends to screen the genetic predisposition genes with high-throughput sequencing for high risk patients with family hereditary breat/ovarian cancers, so that proactive prevention or guided therapies can be adopted. All these guidelines indicate that individualized therapy and prevention based on genetic testing is the new direction for the remedy of breast cancer.